How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Dementia Associated with Alzimer's Disease Market
- By Treatment Type: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Combination Therapy, Symptomatic Treatment, Emerging Therapies
- By Disease Stage: Mild Alzheimer's Disease, Moderate Alzheimer's Disease, Severe Alzheimer's Disease
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
- By Patient Demographics: Geriatric Patients, Early-Onset Alzheimer's Patients, Caregiver-Dependent Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Cholinesterase Inhibitors leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 11 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 260 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.162 →
- 11 Company Profiles 11 players: SWOT & benchmarking p.170 →
Full report · locked preview
Everything inside the Dementia Associated with Alzimer's Disease Market report
A complete, evidence-based study - 11 chapters and 109 sections covering market size, segmentation across 4 axes, regional analysis and 11 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Disease Stage 3
Distribution Channel 4
Patient Demographics 3
Companies profiled
Eli Lilly and Company
Biogen Inc.
Roche Holding AG
Novartis AG
ACADIA Pharmaceuticals Inc.
Axsome Therapeutics Inc.
H. Lundbeck A/S
Otsuka Pharmaceutical Co. Ltd.
Green Valley Pharmaceuticals
Cassava Sciences Inc.
Anavex Life Sciences Corp.
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
11 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Biogen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ACADIA Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Axsome Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →H. Lundbeck A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Otsuka Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Green Valley Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Cassava Sciences Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Anavex Life Sciences Corp.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,796M by 2033 · 4.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Cholinesterase Inhibitors53.3
- NMDA Receptor Antagonists7.7
- Combination Therapy7.9
- Symptomatic Treatment15.4
- Emerging Therapies15.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$410.9M → $660.0M · 6.1%
Europe$286.4M → $421.2M · 4.9%
Asia Pacific$261.5M → $341.6M · 3.4%
Latin America$161.9M → $256.1M · 5.9%
Middle East and Africa$124.5M → $174.3M · 4.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.632026
4.662027
4.662028
4.662029
4.692030
4.702031
4.712032
4.722033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Eli Lilly and Company11.9
- Biogen Inc.12.1
- Roche Holding AG13.0
- Novartis AG11.7
- ACADIA Pharmaceuticals Inc.11.7
- Axsome Therapeutics Inc.11.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type11.2%
Disease Stage28.9%
Distribution Channel29.8%
Patient Demographics30.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.6
- Europe22.7
- Asia Pacific18.4
- Latin America13.8
- Middle East and Africa9.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | 92 | 90 | 81 | 78 | 83 | 80 | 84 |
| Biogen Inc. | 74 | 91 | 71 | 73 | 82 | 76 | 78 |
| Roche Holding AG | 82 | 77 | 75 | 71 | 66 | 87 | 76 |
| Novartis AG | 68 | 61 | 64 | 80 | 57 | 60 | 65 |
| ACADIA Pharmaceuticals Inc. | 76 | 65 | 56 | 63 | 73 | 52 | 64 |
| Axsome Therapeutics Inc. | 61 | 65 | 66 | 63 | 55 | 54 | 61 |
| H. Lundbeck A/S | 58 | 49 | 43 | 58 | 46 | 48 | 50 |
| Otsuka Pharmaceutical Co. Ltd. | 49 | 47 | 46 | 47 | 45 | 36 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Eli Lilly and Company
- Biogen Inc.
- Roche Holding AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Biogen Inc. | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Roche Holding AG | ✓ | ✓ | ✓ | − | ◐ | ✓ |
| Novartis AG | ◐ | − | ✓ | ✓ | − | ◐ |
| ACADIA Pharmaceuticals Inc. | ✓ | ◐ | − | − | ✓ | ◐ |
| Axsome Therapeutics Inc. | − | ◐ | ✓ | ✓ | ◐ | − |
| H. Lundbeck A/S | ◐ | ◐ | − | ◐ | − | ◐ |
| Otsuka Pharmaceutical Co. Ltd. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Eli Lilly and Company84
2Biogen Inc.78
3Roche Holding AG76
4Novartis AG65
5ACADIA Pharmaceuticals Inc.64
6Axsome Therapeutics Inc.61
7H. Lundbeck A/S50
8Otsuka Pharmaceutical Co. Ltd.45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Eli Lilly and CompanyBiogen Inc.
Challenger1
Strong scale, closing on the leaders.
Roche Holding AG
Contender3
Focused players with pockets of strength.
Novartis AGACADIA Pharmaceuticals Inc.Axsome Therapeutics Inc.
Niche2
Specialists in a single segment or region.
H. Lundbeck A/SOtsuka Pharmaceutical Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Dementia Associated with Alzimer's Disease Market — a $459M beachhead inside a $6.93B market.
Beachhead (SOM)$459Mobtainable near-term
Serviceable (SAM)$2.84Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Cholinesterase Inhibitors
Best fit — highest urgency & budget in Treatment Type.
Economic buyer80 fit
NMDA Receptor Antagonists
Strong fit — clear ROI and a fast path to value.
End user65 fit
Combination Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Disease Stage & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Distribution Channel
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel28%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Dementia Associated with Alzimer's Disease Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified20%
Evaluation13%
Closed-won5%
$14.4KCAC
$62KLTV
4.3:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Dementia Associated with Alzimer's Disease Market is a durable-growth opportunity — $8.83B by 2033, compounding at 9.5%.
TAM · 2025$4.28Btoday
TAM · 2033$8.83Bforecast
CAGR9.5%2027–2033
Cumulative$56.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.83BTotal addressable market
SAM$3.23BServiceable available market
SOM$579MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.5% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
11+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.83BLarge & growingTAM by 2033 at 9.5% CAGR
$3.23BServiceable nowreachable with today’s model
$579MBeachhead winobtainable near-term share
11+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.89BBear6.2% CAGR
$8.83BBase9.5% CAGR
$11.3BBull12.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Disease Stage optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Dementia Associated with Alzimer's Disease Market — a $8.35B market by 2033. Plan: grow share from 7.3% to 13.0%.
Market size · 2033$8.35Btotal addressable
Market CAGR5.9%2027–2033
Target share13.0%from 7.3% today
Revenue ambition$1.09Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.3% | 13.0% | On track |
| Revenue | $635M | $1.09B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 37.8% | 41.4% | Ahead |
| Customer retention | 88.9% | 96.0% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Disease Stage capability
A defensible second engine — invest in Disease Stage to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Disease Stage
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $133M capacity & capability investment
- Greenlight bolt-on M&A in Disease Stage
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Dementia Associated with Alzimer's Disease Market conversation — a $6.69B market you can size, segment and defend in minutes.
Market size · 2033$6.69Btotal opportunity
Growth8.7%CAGR to 2033
Addressable buyers1,728+accounts in scope
Typical ROI4.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.4×return on cost, year one
< 3 mopayback period
$67K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
11+players profiled in this market
Coverage includes
Eli Lilly and CompanyBiogen Inc.Roche Holding AGNovartis AGACADIA Pharmaceuticals Inc.Axsome Therapeutics Inc.H. Lundbeck A/SOtsuka Pharmaceutical Co. Ltd.+3 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Dementia Associated with Alzimer's Disease Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Dementia Associated with Alzimer's Disease Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Carb Blocker Supplements Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportCarcinoid Syndrome Diarrhea Treatment Market
Market size, share, segmentation and regional forecast.
$962M market · 2025 base year
View reportCardiac Autonomic Neuropathy Treatment Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportCardiac Catheters and Guidewires Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportCardiac Guidewires Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportCardiac Imaging Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportCardiac Implants Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportCardiac ultrasound transducers Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportCardioplegia Delivery Systems Market
Market size, share, segmentation and regional forecast.
$743M market · 2025 base year
View reportCardiopulmonary Autotransfusion Devices Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportCaries Detection Device Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCartilage Regeneration Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.